Stuart Roberts, F Fin, MAICD

I have been involved in the healthcare and biotechnology sector since the early 2002, initially as a sell-side analyst doing equities research in the sector in Australia, then, from the start of 2015, as an executive inside biotech companies, before I returned to equities research with the founding of NDF Research in June 2016.

Experience
NDF Research, Jun '16 onwards
Founder and Senior Analyst
Imugene, Jan '16 to May '16
Head of Corporate Development, representing Imugene to the capital markets
Prima BioMed, Jan '15 to Nov '15
Head of Investor Relations, representing Prima to the capital markets
Baillieu Holst, Oct '13 to Jan '15
Senior Analyst, covering healthcare as well as telcos/new media
Bell Potter Securities, Jul '11 to Jun '13
Senior Equities Analyst, covering healthcare
Southern Cross Equities, Apr '01 to Jun '11
Equities Analyst, covering healthcare from February 2002. Southern Cross Equities was acquired by Bell Potter Securities in 2008 on a three-year earn-out which completed in June 2011.
The Intelligent Investor, Apr '99 to Apr '01
Analyst, with a generalist focus.

Education and Qualifications
RG146 qualifications, 2016
Qualified in Generic Knowledge and Securities for General Advice
Securities Institute of Australia, 2001
Master of Applied Finance and Investment degree
Securities Institute of Australia, 1994 and 1999
Certificate of Financial Markets (1994), Graduate Diploma in Finance and Investment (1999)
Francis Greenway High School, Beresfield, NSW, 1988
Higher School Certificate

Professional Associations
FINSIA
Fellow (F Fin)

Testimonals
“Stuart Roberts matches up with the best of the best in the healthcare space. He goes beyond the numbers and science to understand the personalities and teams which require good people instincts and finesse. Stu was instrumental in getting Australian investors to rally around Reva’s story when we launched the largest medtech IPO in Australia’s history in 2010…I am delighted he’s returned to his roots in research, investors will benefit greatly from his insights.” - Bob Stockman, Former Chairman & CEO, REVA Medical, Inc.
“I have had the great pleasure of knowing Stuart for almost a decade, and have witnessed first-hand his remarkable skills as an analyst in the life sciences industry.  Among Stuart's many attributes is his uncanny ability to understand science and business, and precisely to hone his opinion based on both fact and informed intuition.  He is creative in his systematic approach to understanding value propositions, risks and likelihoods of success, and importantly, he has a photographic memory.  Stuart knows people, and treats them fairly and with profound humor.  It is an honor to work with Stuart.” - Dr John Holaday, Executive Chairman, ExoCyte Therapeutics.
"Given Stuart Roberts’ reputation and experience in equities analysis in the Life Sciences sector we were very pleased when he reported on Cynata in May 2014.  He went far beyond the extra mile in getting to understand our company in order to accurately report on its fundamentals. The report he produced was detailed, thorough, and in particular designed to correctly position our company in context of what he and we believe is a healthcare revolution taking place in the field of regenerative medicine. I admire the passion, energy and thoroughness that Stuart brings to the task of understanding early stage Life Science companies." - Dr Ross Macdonald, CEO, Cynata Therapeutics.
"Through the vicissitudes that have confronted Australia's burgeoning healthcare and biotechnology markets over the past 15 years there has been one constant - the indefatigable Stuart Roberts. Stuart has an engaging personality, an enquiring mind and an ability to translate into the lingua franca the complex and diverse issues with with which we wrestle. His recent return to equities analysis will be broadly welcomed and will assist many in making reasoned investment decisions in our thorny field" - Dr Geoff Cumming, Former CEO, Anteo Diagnostics.
Copyright © 2016 NDF Research